2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Sales - EUR | 123.512 | 122.305 | 78.807 | 69.246 | 91.484 | 82.945 | 68.632 | 81.181 | 89.129 | 101.469 |
Total Income - EUR | 123.522 | 122.447 | 138.013 | 69.246 | 91.484 | 83.220 | 68.637 | 81.801 | 89.134 | 101.484 |
Total Expenses - EUR | 120.973 | 128.314 | 132.320 | 93.220 | 82.083 | 57.332 | 70.096 | 98.914 | 75.350 | 83.364 |
Gross Profit/Loss - EUR | 2.549 | -5.867 | 5.693 | -23.974 | 9.402 | 25.888 | -1.459 | -17.113 | 13.784 | 18.120 |
Net Profit/Loss - EUR | 1.889 | -6.648 | 4.369 | -24.304 | 8.487 | 25.059 | -2.742 | -17.931 | 12.892 | 17.296 |
Employees | 2 | 0 | 2 | 3 | 3 | 2 | 2 | 1 | 1 | 1 |
Check the financial reports for the company - E&A Pharma Grup Srl
2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Fixed Assets | 10.818 | 10.719 | 0 | 0 | 0 | 0 | 37.910 | 25.080 | 15.122 | 6.009 |
Current Assets | 111.149 | 40.703 | 45.971 | 28.949 | 41.271 | 45.181 | 30.877 | 24.909 | 32.097 | 52.797 |
Inventories | 60.170 | 23.654 | 5.350 | 0 | 0 | 3.930 | 2.898 | -339 | 1.274 | 10.987 |
Receivables | 19.928 | 8.416 | 2.037 | 25.016 | 37.609 | 40.116 | 27.414 | 24.401 | 30.110 | 40.763 |
Cash | 31.051 | 8.634 | 38.584 | 3.933 | 3.662 | 1.135 | 566 | 847 | 713 | 1.047 |
Shareholders Funds | 36.692 | 30.350 | 28.051 | 6.911 | 15.271 | 40.034 | 36.533 | 17.792 | 30.739 | 47.942 |
Social Capital | 112 | 112 | 111 | 109 | 107 | 105 | 103 | 101 | 101 | 101 |
Debts | 85.275 | 21.072 | 17.920 | 22.038 | 26.000 | 5.147 | 32.254 | 32.197 | 16.479 | 10.864 |
Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Exchange rate - RON | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 | 4.4821 |
Main CAEN | "4773 - 4773" | |||||||||
CAEN Financial Year |
4773
|
Subscriptions Financial Reports
You can check the financial situation of the companies in relation to the industry of which it is a part, credit limits and the risk of insolvency and suspension of accounts.
Comments - E&A Pharma Grup Srl